The high prevalence of modifiable risk factors among individuals with diabetes but also the recent emerge of new therapies with favorable effects on CVD outcome, such as sodium-glucose cotransporter-2 inhibitors, underscore the importance of identifying those who would most probably benefit from initiation or optimizing treatment. This evidence concerns the gene SLC5A2 and diabetes mellitus.